<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439151</url>
  </required_header>
  <id_info>
    <org_study_id>2014-KE-143</org_study_id>
    <nct_id>NCT02439151</nct_id>
  </id_info>
  <brief_title>New Lung Ventilation Strategies Guided by Transpulmonary Pressure in VV-ECMO for Severe ARDS</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rui Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe acute
      respiratory distress syndrome (ARDS). But how to choose mechanical ventilation strategy is
      still not clear for severe ARDS patients supported by ECMO. Our previous work found that,
      compared to the traditional &quot;lung rest&quot; strategy, transpulmonary pressure guide new lung
      ventilation strategy can better maintain lung volume reduction lung collapse, atelectasis
      occurs. The severe ARDS patients receiving ECMO therapy were randomized divided into a new
      ventilation strategy group and the conventional ventilation strategy group. The new
      ventilation strategy is transpulmonary pressure guide ventilator setting method, and the
      conventional ventilation strategy is Extracorporeal Life Support Organization (ELSO) guide
      ventilation method. Compare the difference between the two groups of patients in lung injury,
      and explore the lung protection mechanism of new lung ventilation strategies guided by
      transpulmonary pressure. Our research group considered that transpulmonary pressure guide new
      lung ventilation strategy can provide more effective lung protection. And it will be further
      used in clinical work.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">June 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion weaned from VV-ECMO</measure>
    <time_frame>After patients randomized grouping 60 days</time_frame>
    <description>Respiratory failure was alleviated and then ECMO withdrawal could be considered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>60-day mortality</measure>
    <time_frame>After patients randomized grouping 60 days</time_frame>
    <description>Mortality after patients randomized grouping 60 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>New Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New lung ventilation strategy</intervention_name>
    <description>New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.</description>
    <arm_group_label>New Strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional ventilation strategy</intervention_name>
    <description>Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.</description>
    <arm_group_label>Conventional Strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ARDS cause reversible;

          -  Pure oxygen is given, but PaO2/FiO2＜80;

          -  P(A-a)O2＞600mmHg;

          -  Murray score≥3.0;

          -  pH＜7.2;

        Exclusion Criteria:

          -  peak inspiratory pressure＞30cmH2O;

          -  high FiO2＞0.8;

          -  ventilation＞7 days;

          -  contraindication to heparinization;

          -  non-reversible central nervous system injury

          -  chronic disease with a short life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Sun, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Rui Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal Membrane Oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

